Payment overview · 2025
General Payments
$983.86
50 reported records · 15 companies
Healthcare provider profile · identity verified
Kyle Bruyninckx, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RAYVILLE, LA · NPI 1972770378
Verified facts
What the public records show
CMS Open Payments records show Kyle Bruyninckx, MD received $983.86 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt, Ozempic, Rybelsus, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 599 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 384 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $280.76 | 28.5% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $113.18 | 11.5% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.06 | 10.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.12 | 7.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.13 | 6.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.49 | 6.2% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $52.62 | 5.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $47.81 | 4.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.88 | 3.5% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $32.54 | 3.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.27 | 3.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.53 | 3.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.67 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.20 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $983.86 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.16 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.43 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.06 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.53 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.13 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.13 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.49 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.67 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.19 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $52.62 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $47.81 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.65 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.88 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.88 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $32.54 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $32.54 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $32.54 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.53 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 384 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 599 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 144 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
200 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
599 | 100 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
144 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
384 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
66 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 1540 | 446 |
| Gabapentin | Gabapentin | 1420 | 348 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1364 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1095 | 223 |
| Fluticasone Propionate | Fluticasone Propionate | 1081 | 358 |
| Losartan Potassium | Losartan Potassium | 1059 | 272 |
| Hydrochlorothiazide | Hydrochlorothiazide | 1050 | 286 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1042 | 243 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 999 | 352 |
| Amlodipine Besylate | Amlodipine Besylate | 764 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 193 |
| Furosemide | Furosemide | 695 | 172 |
| Nifedipine Er | Nifedipine | 664 | 183 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 664 | 184 |
| Potassium Chloride | Potassium Chloride | 658 | 134 |
| Metformin Hcl | Metformin Hcl | 654 | 162 |
| Ozempic | Semaglutide | 599 | 100 |
| Trazodone Hcl | Trazodone Hcl | 587 | 148 |
| Omeprazole | Omeprazole | 534 | 135 |
| Mounjaro | Tirzepatide | 515 | 77 |
| Azithromycin | Azithromycin | 487 | 333 |
| Carvedilol | Carvedilol | 485 | 109 |
| Lisinopril | Lisinopril | 474 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 445 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 437 | 121 |
| Diclofenac Sodium | Diclofenac Sodium | 429 | 140 |
| Sertraline Hcl | Sertraline Hcl | 413 | 94 |
| Buspirone Hcl | Buspirone Hcl | 392 | 90 |
| Eliquis | Apixaban | 384 | 72 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 383 | 261 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 382 | 121 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 358 | 127 |
| Glimepiride | Glimepiride | 335 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 324 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 302 | 77 |
| Tramadol Hcl | Tramadol Hcl | 277 | 114 |
| Pregabalin | Pregabalin | 272 | 61 |
| Celecoxib | Celecoxib | 264 | 62 |
| Prednisone | Prednisone | 245 | 163 |
| Allopurinol | Allopurinol | 238 | 46 |
| Simvastatin | Simvastatin | 238 | 49 |
| Clonidine Hcl | Clonidine Hcl | 236 | 78 |
| Memantine Hcl | Memantine Hcl | 222 | 47 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 222 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 222 | 58 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 219 | 158 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 218 | 113 |
| Meloxicam | Meloxicam | 207 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 206 | 49 |
| Linzess | Linaclotide | 200 | 55 |
| Trulicity | Dulaglutide | 193 | 42 |
| Ondansetron Odt | Ondansetron | 187 | 95 |
| Amitriptyline Hcl | Amitriptyline Hcl | 186 | 31 |
| Clonidine | Clonidine | 174 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 174 | 38 |
| Sucralfate | Sucralfate | 166 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 156 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 44 |
| Rybelsus | Semaglutide | 144 | 32 |
| Alendronate Sodium | Alendronate Sodium | 138 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 136 | 99 |
| Alprazolam | Alprazolam | 130 | 37 |
| Colchicine | Colchicine | 126 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 29 |
| Aripiprazole | Aripiprazole | 120 | 18 |
| Clonazepam | Clonazepam | 117 | 18 |
| Lovastatin | Lovastatin | 112 | 26 |
| Entresto | Sacubitril/Valsartan | 111 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 24 |
| Levofloxacin | Levofloxacin | 110 | 88 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 21 |
| Famotidine | Famotidine | 108 | 22 |
| Temazepam | Temazepam | 108 | 27 |
| Fluconazole | Fluconazole | 103 | 59 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 103 | 77 |
| Donepezil Hcl | Donepezil Hcl | 101 | 26 |
| Levetiracetam | Levetiracetam | 99 | 20 |
| Glipizide | Glipizide | 98 | 25 |
| Finasteride | Finasteride | 97 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 91 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 86 | 55 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 22 |
| Meclizine Hcl | Meclizine Hcl | 80 | 42 |
| Lansoprazole | Lansoprazole | 79 | 16 |
| Mupirocin | Mupirocin | 78 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 13 |
| Jardiance | Empagliflozin | 77 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 18 |
| Methocarbamol | Methocarbamol | 75 | 23 |
| Cefprozil | Cefprozil | 74 | 58 |
| Spironolactone | Spironolactone | 74 | 19 |
| Valacyclovir | Valacyclovir Hcl | 74 | 29 |
| Bumetanide | Bumetanide | 72 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 15 |
| Ezetimibe | Ezetimibe | 67 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 66 | 65 |
| Lorazepam | Lorazepam | 65 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 65 | 15 |
| Xarelto | Rivaroxaban | 64 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 49 |
| Ranolazine Er | Ranolazine | 60 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 14 |
| Lactulose | Lactulose | 57 | 19 |
| Primidone | Primidone | 57 | suppressed |
| Baclofen | Baclofen | 55 | 14 |
| Myrbetriq | Mirabegron | 55 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 30 |
| Cephalexin | Cephalexin | 54 | 45 |
| Diazepam | Diazepam | 54 | 18 |
| Estradiol | Estradiol | 54 | 14 |
| Topiramate | Topiramate | 54 | 13 |
| Gemfibrozil | Gemfibrozil | 52 | 11 |
| Memantine Hcl Er | Memantine Hcl | 52 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 52 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | 11 |
| Ibuprofen | Ibuprofen | 50 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Atenolol | Atenolol | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 46 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 34 |
| Sotalol | Sotalol Hcl | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Metronidazole | Metronidazole | 37 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Lidocaine | Lidocaine | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 34 | 34 |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 13 |
| Nitroglycerin | Nitroglycerin | 32 | 18 |
| Nystatin | Nystatin | 32 | 24 |
| Ramipril | Ramipril | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 14 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 11 |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Sotalol Af | Sotalol Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $983.86 · 50 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BEYFORTUS, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, General - Therapies, IBSRELA, JARDIANCE, Kerendia, Korlym, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error